Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > SC 23G/A Filing

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Feb 08, 2024 8:41am

128 Views

Post# 35869392

RE:RE:RE:RE:RE:RE:SC 23G/A Filing

These accumulations by a couple M&A players and latest Soleus comments does bring this prospect to mind. It's an exit strategy if Th1902 is considered an expensive long term long shot. Like some mentioned there is really no light at the end of this endless tunnel.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland